Patents by Inventor Gary Pignac-Kobinger

Gary Pignac-Kobinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein targeting into HIV virions based on HIV-1 VPR fusion molecules
    Patent number: 6468539
    Abstract: The present invention relates to a Vpr protein, a Vpx protein or fragments thereof which permit the development of chimeric molecules that can be specifically targeted into the mature HIV-1 and HIV-2 virions to affect their structural organization and/or functional integrity, thereby resulting in gene therapy for HIV-1 and HIV-2 infections. The present invention also relates to Vpr/Vpx protein Fragments, p6 protein, p6 protein fragment, or functional derivatives thereof which interfere with the native Vpr/Vpx incorporation into HIV-1 and HIV-2 virions. The present invention also relates to treatment of HIV-1 and HIV-2 infections based on the proteins of the present invention.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: October 22, 2002
    Assignee: Universite de Montreal
    Inventors: Eric A. Cohen, Dominique Bergeron, Florent Checroune, Xiao-Jian Yao, Gary Pignac-Kobinger
  • Expression vectors encoding recombinant proteins comprising a VPR/VPX virion incorporation domain for targeting into HIV-1 or HIV-2 virions
    Patent number: 6043081
    Abstract: The present invention relates to a Vpr protein, a Vpx protein or fragments thereof which permit the development of chimeric molecules that can be specifically targeted into the mature HIV-1 and HIV-2 virions to affect their structural organization and/or functional integrity, thereby resulting in gene therapy for HIV-1 and HIV-2 infections. The present invention also relates to Vpr/Vpx protein fragments, p6 protein, p6 protein fragment, or functional derivatives thereof which interfere with the native Vpr/Vpx incorporation into HIV-1 and HIV-2 virions. The present invention also relates to treatment of HIV-1 and HIV-2 infections based on the proteins of the present invention.
    Type: Grant
    Filed: September 7, 1995
    Date of Patent: March 28, 2000
    Assignee: Universite De Montreal
    Inventors: Eric A. Cohen, Dominique Bergeron, Florent Checroune, Xiao-Jian Yao, Gary Pignac-Kobinger
  • Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
    Patent number: 5861161
    Abstract: The present invention is directed toward chimeric human immunodeficiency virus type 1 and 2 (HIV-1 and -2) proteins that are capable of being incorporated into the virion when expressed in trans. These chimeric proteins consist of a first portion comprising an HIV-1 or HIV-2 Vpr/Vpx virion incorporation domain which includes the predicted N-terminal alpha helix. This domain is capable of interacting with the p6 domain of the Pr55.sup.gag. The second portion of the chimera comprises a sequence containing RNase activity, protease activity, or a domain capable of inhibiting virion morphogenesis and assembly. The disclosed invention provides a chimera that affects the structural organization or functional integrity of the mature virion by enzymatic disturbance or steric hindrance of the virion.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: January 19, 1999
    Assignee: Universite de Montreal
    Inventors: Eric A. Cohen, Dominique Bergeron, Florent Checroune, Xiao-Jian Yao, Gary Pignac-Kobinger